{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T17:28:31Z","timestamp":1785864511292,"version":"3.56.0"},"reference-count":34,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"13","license":[{"start":{"date-parts":[[2020,3,1]],"date-time":"2020-03-01T00:00:00Z","timestamp":1583020800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"abstract":"<jats:sec>\n            <jats:title>Abstract<\/jats:title>\n            <jats:p>We herein report a 76-year-old Japanese man with myelofibrosis who developed cryptococcal meningitis. After treatment for 5 months with ruxolitinib, the patient presented with fever and disturbance of consciousness. Marked nuchal stiffness was noted. The magnetic resonance imaging results of the brain were normal. Lumbar puncture showed an opening cerebrospinal fluid (CSF) pressure of 110\u200amm H<jats:sub>2<\/jats:sub>O, pleocytosis (85 mononuclear cells and 222 polymorphonuclear cells\/\u03bcL), decreased CSF\/serum glucose ratio (43%), and elevated protein (194\u200amg\/dL). Blood and CSF cultures grew no bacteria or fungi. However, cryptococcal antigen was detected in the blood and CSF samples. We discontinued ruxolitinib and started administration of amphotericin B. His condition improved gradually 1\u200aweek after initiation of treatment. There have been only a few reports on cryptococcal meningitis associated with ruxolitinib. Physicians should consider the possibility of cryptococcal meningitis in patients receiving ruxolitinib.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/md.0000000000019587","type":"journal-article","created":{"date-parts":[[2020,3,28]],"date-time":"2020-03-28T00:18:36Z","timestamp":1585354716000},"page":"e19587","source":"Crossref","is-referenced-by-count":10,"title":["A case report of cryptococcal meningitis associated with ruxolitinib"],"prefix":"10.1097","volume":"99","author":[{"given":"Daisuke","family":"Tsukui","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroaki","family":"Fujita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keisuke","family":"Suzuki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koichi","family":"Hirata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2020,3]]},"reference":[{"key":"R1-20230915","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1056\/NEJMoa1110556","article-title":"JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis","volume":"366","author":"Harrison","year":"2012","journal-title":"N Engl J Med"},{"key":"R2-20230915","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1056\/NEJMoa1110557","article-title":"A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis","volume":"366","author":"Verstovsek","year":"2012","journal-title":"N Engl J Med"},{"key":"R3-20230915","doi-asserted-by":"crossref","first-page":"1933","DOI":"10.1158\/1078-0432.CCR-12-0284","article-title":"Molecular pathways: Jak\/STAT pathway: mutations, inhibitors, and resistance","volume":"19","author":"Quintas-Cardama","year":"2013","journal-title":"Clin Cancer Res"},{"key":"R4-20230915","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1182\/blood-2013-03-484642","article-title":"The JAK-inhibitor ruxolitinib impairs dendritic cell function in vitro and in vivo","volume":"122","author":"Heine","year":"2013","journal-title":"Blood"},{"key":"R5-20230915","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1111\/bjh.13373","article-title":"JAK1\/2 inhibition impairs T cell function in vitro and in patients with myeloproliferative neoplasms","volume":"169","author":"Parampalli Yajnanarayana","year":"2015","journal-title":"Br J Haematol"},{"key":"R6-20230915","doi-asserted-by":"crossref","first-page":"2187","DOI":"10.1158\/0008-5472.CAN-14-3198","article-title":"JAK inhibition impairs NK cell function in myeloproliferative neoplasms","volume":"75","author":"Schonberg","year":"2015","journal-title":"Cancer Res"},{"key":"R7-20230915","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1038\/nrneurol.2016.167","article-title":"Cryptococcal meningitis: epidemiology, immunology, diagnosis and therapy","volume":"13","author":"Williamson","year":"2017","journal-title":"Nat Rev Neurol"},{"issue":"(Pt 8)","key":"R8-20230915","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1242\/jcs.00963","article-title":"The JAK\/STAT signaling pathway","volume":"117","author":"Rawlings","year":"2004","journal-title":"J Cell Sci"},{"key":"R9-20230915","doi-asserted-by":"crossref","first-page":"2623","DOI":"10.4049\/jimmunol.178.5.2623","article-title":"The JAK-STAT signaling pathway: input and output integration","volume":"178","author":"Murray","year":"2007","journal-title":"J Immunol"},{"key":"R10-20230915","doi-asserted-by":"crossref","first-page":"e270","DOI":"10.1371\/journal.pmed.0030270","article-title":"MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia","volume":"3","author":"Pikman","year":"2006","journal-title":"PLoS Med"},{"key":"R11-20230915","doi-asserted-by":"crossref","first-page":"1988","DOI":"10.1158\/1078-0432.CCR-09-2836","article-title":"Therapeutic potential of Janus-activated kinase-2 inhibitors for the management of myelofibrosis","volume":"16","author":"Verstovsek","year":"2010","journal-title":"Clin Cancer Res"},{"key":"R12-20230915","doi-asserted-by":"crossref","first-page":"171","DOI":"10.3322\/caac.20009","article-title":"Advances in understanding and management of myeloproliferative neoplasms","volume":"59","author":"Vannucchi","year":"2009","journal-title":"CA Cancer J Clin"},{"key":"R13-20230915","doi-asserted-by":"crossref","first-page":"3109","DOI":"10.1182\/blood-2009-04-214957","article-title":"Preclinical characterization of the selective JAK1\/2 inhibitor INCB018424: therapeutic implications for the treatment of myeloproliferative neoplasms","volume":"115","author":"Quintas-Cardama","year":"2010","journal-title":"Blood"},{"key":"R14-20230915","doi-asserted-by":"crossref","first-page":"1585","DOI":"10.3324\/haematol.11506","article-title":"Somatic mutations of JAK2 exon 12 as a molecular basis of erythrocytosis","volume":"92","author":"Cazzola","year":"2007","journal-title":"Haematologica"},{"key":"R15-20230915","doi-asserted-by":"crossref","first-page":"1356","DOI":"10.1200\/JCO.2010.32.9490","article-title":"Circulating interleukin (IL)-8, IL-2R, IL-12, and IL-15 levels are independently prognostic in primary myelofibrosis: a comprehensive cytokine profiling study","volume":"29","author":"Tefferi","year":"2011","journal-title":"J Clin Oncol"},{"key":"R16-20230915","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1186\/s12879-019-3922-6","article-title":"A case report of disseminated histoplasmosis and concurrent cryptococcal meningitis in a patient treated with ruxolitinib","volume":"19","author":"Prakash","year":"2019","journal-title":"BMC Infect Dis"},{"key":"R17-20230915","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1007\/s00277-015-2532-7","article-title":"Cryptococcal meningoencephalitis associated with the long-term use of ruxolitinib","volume":"95","author":"Chen","year":"2016","journal-title":"Ann Hematol"},{"key":"R18-20230915","first-page":"87","article-title":"Pulmonary cryptococcosis in a ruxolitinib-treated patient with primary myelofibrosis","volume":"22","author":"Hirano","year":"2017","journal-title":"Respir Med Case Rep"},{"key":"R19-20230915","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1111\/myc.12735","article-title":"Fulminant Cryptococcus neoformans infection with fatal pericardial tamponade in a patient with chronic myelomonocytic leukaemia who was treated with ruxolitinib: case report and review of fungal pericarditis","volume":"61","author":"Liu","year":"2018","journal-title":"Mycoses"},{"key":"R20-20230915","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1056\/NEJMc1302895","article-title":"Bilateral toxoplasmosis retinitis associated with ruxolitinib","volume":"369","author":"Goldberg","year":"2013","journal-title":"N Engl J Med"},{"key":"R21-20230915","doi-asserted-by":"crossref","DOI":"10.1136\/bcr-2014-204950","article-title":"Pneumocystis jiroveci pneumonitis complicating ruxolitinib therapy","volume":"2014","author":"Lee","year":"2014","journal-title":"BMJ Case Rep"},{"key":"R22-20230915","doi-asserted-by":"crossref","first-page":"1478","DOI":"10.1378\/chest.12-1604","article-title":"An opportunistic infection associated with ruxolitinib, a novel janus kinase 1,2 inhibitor","volume":"143","author":"Wysham","year":"2013","journal-title":"Chest"},{"key":"R23-20230915","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1056\/NEJMc1302135","article-title":"Progressive multifocal leukoencephalopathy associated with ruxolitinib","volume":"369","author":"Wathes","year":"2013","journal-title":"N Engl J Med"},{"key":"R24-20230915","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1186\/1756-0500-5-552","article-title":"Disseminated tuberculosis in a patient treated with a JAK2 selective inhibitor: a case report","volume":"5","author":"Colomba","year":"2012","journal-title":"BMC Res Notes"},{"key":"R25-20230915","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1007\/s00277-013-1936-5","article-title":"Hepatitis B virus reactivation associated with ruxolitinib","volume":"93","author":"Shen","year":"2014","journal-title":"Ann Hematol"},{"key":"R26-20230915","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1097\/QAD.0b013e328333c005","article-title":"Histopathology of the arachnoid granulations and brain in HIV-associated cryptococcal meningitis: correlation with cerebrospinal fluid pressure","volume":"24","author":"Loyse","year":"2010","journal-title":"AIDS"},{"key":"R27-20230915","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1097\/QAD.0b013e32832605fe","article-title":"Relationship of cerebrospinal fluid pressure, fungal burden and outcome in patients with cryptococcal meningitis undergoing serial lumbar punctures","volume":"23","author":"Bicanic","year":"2009","journal-title":"AIDS"},{"key":"R28-20230915","doi-asserted-by":"crossref","first-page":"1701","DOI":"10.1038\/leu.2016.148","article-title":"Long-term findings from COMFORT-II, a phase 3 study of ruxolitinib vs best available therapy for myelofibrosis","volume":"30","author":"Harrison","year":"2016","journal-title":"Leukemia"},{"key":"R29-20230915","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1080\/23744235.2017.1390248","article-title":"Infectious complications in patients on treatment with ruxolitinib: case report and review of the literature","volume":"50","author":"Dioverti","year":"2018","journal-title":"Infect Dis (Lond)"},{"issue":"(Suppl 1)","key":"R30-20230915","doi-asserted-by":"crossref","first-page":"i34","DOI":"10.1093\/rheumatology\/key287","article-title":"Growing evidence of the safety of JAK inhibitors in patients with rheumatoid arthritis","volume":"58","author":"Harigai","year":"2019","journal-title":"Rheumatology (Oxford)"},{"key":"R31-20230915","doi-asserted-by":"crossref","first-page":"169","DOI":"10.2147\/TCRM.S121683","article-title":"Ruxolitinib in myelofibrosis: to be or not to be an immune disruptor","volume":"13","author":"Manduzio","year":"2017","journal-title":"Ther Clin Risk Manag"},{"key":"R32-20230915","first-page":"95","article-title":"Ruxolitinib for the treatment of myelofibrosis: its clinical potential","volume":"8","author":"Ostojic","year":"2012","journal-title":"Ther Clin Risk Manag"},{"key":"R33-20230915","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1128\/EC.05273-11","article-title":"Adaptation of Cryptococcus neoformans to mammalian hosts: integrated regulation of metabolism and virulence","volume":"11","author":"Kronstad","year":"2012","journal-title":"Eukaryot Cell"},{"key":"R34-20230915","doi-asserted-by":"crossref","first-page":"4060","DOI":"10.4049\/jimmunol.1103455","article-title":"Protective immunity against pulmonary cryptococcosis is associated with STAT1-mediated classical macrophage activation","volume":"189","author":"Hardison","year":"2012","journal-title":"J Immunol"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000019587","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,15]],"date-time":"2023-09-15T21:26:46Z","timestamp":1694813206000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000019587"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,3]]},"references-count":34,"journal-issue":{"issue":"13","published-online":{"date-parts":[[2020]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000019587","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"value":"0025-7974","type":"print"},{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,3]]}}}